← The Wire
SNDXNasdaq
Syndax Pharmaceuticals Inc
Pharmaceutical Preparations · DE · CIK 1395937
Syndax Pharmaceuticals develops combination cancer therapies, including revumenib and axatilimab
red 8-K · 90d
$1.62B
Market cap
$21.78
Last close
+2.2%
1D
+12.7%
5D
4.7M
Volume
Price · last 39 sessions+9.1%
May 4L $16.96 · H $21.78Jun 29
227
Total filings
Jun 10, 2026
Last filing
12/31
Fiscal year end
DEF 14ADEF 14AApr 30, 2026DEF 14ADEF 14AApr 1, 2025DEF 14ADEF 14AApr 2, 2024DEF 14ADEF 14AApr 7, 2023DEF 14ADEF 14AMar 29, 2022DEF 14ADEF 14AApr 1, 2021DEF 14ADEF 14AApr 29, 2020DEF 14ADEF 14AApr 30, 2019DEF 14ADEF 14AApr 10, 2018DEF 14ADEFINITIVE PROXY STATEMENTApr 7, 2017
Insider Activity
In the 90 days to Feb 9, 2026: 2 sold $628K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 9, 2026 | Metzger Michael AChief Executive Officer | Sell | 17,159 | $21.03 | $361K |
| Feb 9, 2026 | Goldan Keith A.Chief Financial Officer | Sell | 3,410 | $21.03 | $72K |
| Feb 6, 2026 | Metzger Michael AChief Executive Officer | Sell | 7,412 | $20.62 | $153K |
| Feb 6, 2026 | Goldan Keith A.Chief Financial Officer | Sell | 2,082 | $20.62 | $43K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance